Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

Trial Profile

An Open-Label Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs PCS 499 (Primary)
  • Indications Necrobiosis lipoidica
  • Focus Adverse reactions
  • Sponsors Processa Pharmaceuticals
  • Most Recent Events

    • 09 Jan 2019 According to a Processa Pharmaceuticals media release, the study was led by Dr. Misha Rosenbach at the Perelman School of Medicine at the University of Pennsylvania.
    • 09 Jan 2019 According to a Processa Pharmaceuticals media release, the American Academy of Dermatology (AAD) has selected presentation on the Study Design and Preliminary data of this trial or an oral presentation and ePoster at the 2019 Annual Meeting.
    • 21 Nov 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top